# Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

> **NCT07087912** · PHASE4 · RECRUITING · sponsor: **University of Sao Paulo General Hospital** · enrollment: 477 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)
- Juvenile Idiopathic Arthritis (JIA)
- Systemic Lupus Erythematosus (SLE)
- Juvenile Systemic Lupus Erythematosus
- Systemic Sclerosis (SSc)
- Idiopathic Inflammatory Myopathies (IIMs)
- Axial Spondyloarthritis
- Psoriatic Arthritis (PsA)
- Granulomatosis With Polyangiitis
- Microscopic Polyangiitis
- Antiphospholipid Syndrome
- Takayasu Arteritis

## Interventions

- **BIOLOGICAL:** Dengue 1,2,3,4 (attenuated) vaccine

## Key facts

- **NCT ID:** NCT07087912
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 477 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07087912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07087912, "Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07087912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*